19
https://pubmed.ncbi.nlm.nih.gov/38113652
A patient with metastatic lung atypical carcinoid and an ETV6::NTRK3 gene fusion achieved a partial response for over ten months when treated with repotrectinib.
“Patient with Metastatic Lung Atypical Carcinoid and ETV6::NTRK3 Fusion Achieves Long-Term Response to Repotrectinib Treatment”
